Published 4 hours ago • loading... • Updated 4 hours ago
Canaccord Genuity Group Has Lowered Expectations for Aclaris Therapeutics (NASDAQ:ACRS) Stock Price
Summary by MarketBeat
1 Articles
1 Articles
Canaccord Genuity Group Has Lowered Expectations for Aclaris Therapeutics (NASDAQ:ACRS) Stock Price
Canaccord Genuity Group decreased their price objective on Aclaris Therapeutics from $13.00 to $12.00 and set a "buy" rating on the stock in a research note on Tuesday.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last Updated100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium






